Therefore, we aimed to evaluate the prognostic efficacy of serum Krebs von den Lungen-6 (KL-6) for DP in patients with IPF receiving antifibrotic therapy. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.